This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for COVID-19 Screening Program (NCT05216627), a registered phase not stated study. The primary outcome is Use of a Voluntary COVID-19 Point of Care (POC) Screening Program.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT05216627 |
| Phase | Phase not stated |
| Condition | COVID-19 |
| Allocation | Not Stated |
| Design model | Not Stated |
| Masking | Not Stated |
| Enrollment | 61 |
| Arms in the primary outcome | n/a |
| Lead sponsor | University of Pennsylvania |
| Results posted | Yes |
2. Clinical Question
Population
University of Pennsylvania faculty, staff, and trainees working in person in Perelman School of Medicine laboratories who chose to participate in the point-of-care screening program. The registry record lists enrollment of 61. Lab-wide completion counts were reported by captains on behalf of participants from their respective labs; 15 captains participated over the course of the program.
Intervention
Access to a voluntary point-of-care COVID-19 screening program that included self-administered saliva-based viral testing. The program was intended to coordinate existing systems and support self-testing. The study description says that results would be self-reported, would not be used to validate tests or support future FDA approval, and would not be entered in participants’ electronic medical records.
Comparator
No like-for-like control comparison is described. The registry record does not state an allocation method, and the study is not described as a randomized comparison. It therefore does not establish a comparison group against which to estimate a treatment effect.
Primary question
How often was the voluntary point-of-care screening program used, measured as the total completed screening tests reported over fourteen weeks? The outcome addresses program uptake and implementation, rather than test accuracy, prevention of infection, or a clinical outcome. The registry record describes how the count was to be gathered, but an observed total is not reported in the registry record.
3. Trial Design
This is an implementation study of a voluntary COVID-19 point-of-care screening program at the University of Pennsylvania’s Perelman School of Medicine. The program was intended for faculty, staff, and trainees working in person in PSOM laboratories. The study description outlines a pilot in a small cohort of labs followed by implementation across PSOM labs for those who wished to participate. It describes coordinating existing systems, including voluntary self-administered saliva-based viral testing.
The registry record lists enrollment of 61 and a status of completed. The recorded study start was 2022-02-07, and primary completion was 2022-07-01. The primary outcome timeframe is fourteen weeks. Captains reported lab-wide screening-test completion to the study team on behalf of participants from their respective labs; 15 captains participated over the course of the program.
This design is descriptive rather than a randomized comparison. The allocation method is not stated, and the registry record does not describe a like-for-like control group. Participation was voluntary, so the program’s participants may differ from people who did not participate; the record does not report a comparison that would quantify such differences. The study description also says that no samples would be collected as part of the study. Self-reported results were not intended to validate tests or support future FDA approval, and the study data were not to be entered in participants’ electronic medical records.
The registry record does not report the protocol details, a sample-size justification, or a statistical analysis plan. The design should therefore be understood from the stated implementation purpose and the outcome definitions, without inferring unrecorded procedures.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Overall Study
| Stage | PSOM Staff, Trainees, or Faculty Who Participate in the Point of Care Testing |
|---|---|
| STARTED | 61 |
| COMPLETED | 61 |
| NOT COMPLETED | 0 |
Analysis population for the primary outcome, as defined in the registry: Lab-wide screening test completion was reported to the study team by captains on behalf of participants from their respective labs. Fifteen captains participated over the course of the program.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | PSOM Staff, Trainees, or Faculty Who Participate in the Point of Care Testing |
|---|---|---|
| Participants analysed | 61 | |
| Age, Continuous | years | 37.9 (SD 14.5) |
| Sex: Female, Male: Female | Participants | 32 |
| Sex: Female, Male: Male | Participants | 29 |
| Ethnicity (NIH/OMB): Hispanic or Latino | Participants | 1 |
| Ethnicity (NIH/OMB): Not Hispanic or Latino | Participants | 59 |
| Ethnicity (NIH/OMB): Unknown or Not Reported | Participants | 1 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 0 |
| Race (NIH/OMB): Asian | Participants | 13 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 0 |
| Race (NIH/OMB): Black or African American | Participants | 4 |
| Race (NIH/OMB): White | Participants | 39 |
| Race (NIH/OMB): More than one race | Participants | 2 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 3 |
| Region of Enrollment: United States | Participants | 61 |
| Study Participation Level: Lab Captains | Participants | 15 |
| Study Participation Level: Non-Captains | Participants | 46 |
6. Primary Endpoint
The registry lists the primary outcome as Use of a Voluntary COVID-19 Point of Care (POC) Screening Program, measured over fourteen weeks.
| Element | Registry entry |
|---|---|
| Result type | Number |
| Measure of spread | not applicable |
| Unit | total completed screening tests reported |
| Endpoint classification | not reduced to a single comparison |
The primary endpoint is the total number of completed point-of-care screening tests reported during fourteen weeks. Its stated purpose is to measure how often participants used the voluntary screening program. Captains reported lab-wide test completion to the study team on behalf of participants from their labs, so this is a program-level usage count rather than an individual clinical outcome or a measure of test accuracy.
A count can describe the volume of activity recorded during a defined period. It can help characterize whether a program was used, but by itself it does not show why people did or did not participate, whether use was appropriate, or whether the testing changed health outcomes. Without a comparator or additional denominators, a total count also cannot establish a difference in use between groups or the proportion of eligible people who completed testing.
The registry record gives the outcome definition and reporting approach, but the observed total is not reported in the registry record. Consequently, the amount of use and its statistical precision cannot be described from the recorded information. The record also does not report details such as the distribution of tests across labs or participants, which would be needed to assess how concentrated the reported activity was.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The primary outcome is a count of completed screening tests reported over fourteen weeks. It is intended to characterize use of the voluntary program, not to estimate a clinical treatment effect. The registry record explains that lab captains reported counts on behalf of participants and that 15 captains participated over the course of the program. However, the observed primary outcome total is not reported in the registry record. There is therefore no reported count to interpret and no basis in this record for describing the extent of uptake.
The record lists enrollment of 61, but enrollment is not interchangeable with the number of completed tests, the number of people who tested, or the number of eligible people who used the program. Those quantities are not reported in the registry record. Nor does the record provide a comparison group or a stated allocation method. A count of program activity cannot, by itself, establish how use would have differed under another approach.
No primary-outcome analysis is reported in the registry record. In particular, no estimate of an effect, confidence interval, or p-value is available to assess magnitude, precision, or statistical compatibility with a null value. General statistical interpretation: a confidence interval describes uncertainty around an estimate under the assumptions of the analysis; it does not address biases from selection, incomplete reporting, or an unsuitable comparison. Without a reported estimate or analysis, these forms of uncertainty cannot be quantified for this outcome.
The study description emphasizes implementation and reports that participants’ results were self-reported. It says the study would not collect samples for validation and would not use results to support future FDA approval. Thus, the program’s reported use should not be treated as evidence about diagnostic accuracy. The record also does not report results showing whether the program affected behavior, decision-making, or infection outcomes.
The record lists 12 outcome measures and no analyses. The absence of reported analysis means there is no basis to claim that a statistical test confirmed or ruled out a difference. Likewise, sample-size planning assumptions are not a substitute for an observed outcome or a completed analysis. Any planning illustration is distinct from observed power and cannot provide evidence about the actual precision of the program’s reported use.
9. Statistical Methods Explained
The primary outcome is a count: total completed screening tests reported over a defined fourteen-week period. The registry record identifies captains as the source of lab-wide reports. It does not report an observed count or a statistical analysis of that count. The distinction matters because an outcome definition explains what was intended to be measured, whereas an analysis requires recorded observations and a stated method for interpreting them.
What does a count measure?
General statistical explanation: a count records how many events occurred within a defined unit and time period. A count can be useful for describing activity, but the interpretation depends on its context. A larger count could reflect more participants, more frequent testing per participant, longer observation, or differences in reporting. To compare rates meaningfully, analysts generally need a relevant denominator or exposure time and a clear comparison. The registry record does not report those elements for interpreting the program’s use beyond the stated total-count outcome.
Counts may also vary substantially between groups or sites. General statistical explanation: count data are often analyzed using methods designed for nonnegative integer outcomes. Some methods assume that variability is tied to the average count; when observed variation is greater than that assumption allows, over-dispersion can make standard errors too small and confidence intervals too narrow. This is a general consideration, not a claim about the distribution in this study. The distribution of reported tests across labs and participants is not reported in the registry record, so over-dispersion cannot be assessed.
What would an estimate and interval tell a reader?
General statistical explanation: an estimate describes the value calculated from the observed data, while a confidence interval conveys statistical uncertainty under the analysis assumptions. A narrow interval indicates greater precision under those assumptions than a wide interval. Neither an estimate nor an interval removes possible bias from volunteer participation, incomplete reporting, or differences between the people or labs being compared. The registry record does not report a primary-outcome estimate or confidence interval, so the magnitude and precision of use cannot be assessed.
A p-value, when used, addresses how compatible data are with a specified statistical model and null hypothesis. It is not a measure of the size or practical importance of an effect. A p-value is not reported for the primary outcome, and no primary-outcome analysis is listed. It would not be appropriate to infer statistical significance from the endpoint description or enrollment count.
How should the planning assumptions be read?
The registry record describes planning illustrations based on an observed effect, equal allocation between two arms, a normal approximation, and a two-sided significance level of 0.05. These are planning assumptions, not evidence that the study had those design features. The allocation method is not stated, and the record does not describe a like-for-like control comparison. The observed effect and any resulting sample-size values are not reported in the registry record. Such illustrations are not observed power and do not replace an analysis of the recorded outcome.
General statistical explanation: sample-size calculations depend on assumptions about the effect to detect, variability, allocation, and the chosen error rate. If the actual design or outcome differs from those assumptions, a planning calculation may not describe the precision achieved. A calculation based on an observed effect is particularly not a prospective justification unless the timing and use of that effect are documented. The registry record does not report a sample-size justification for the study itself.
What can be concluded from the reporting approach?
The reported endpoint is based on captains’ lab-wide accounts, rather than a stated individual-level analysis. General statistical explanation: aggregated reporting can conceal variation within a group. It may describe total program activity while leaving unclear which participants contributed tests and how use varied between labs. The record does not report validation procedures, the completeness of captain reports, or the handling of missing reports. These are uncertainties about measurement and reporting, not proof that the counts were inaccurate.
The record lists no analyses. Therefore, no particular model, adjustment strategy, confidence-interval method, or hypothesis-testing procedure can be attributed to this study. General statistical concepts can clarify what such methods would address, but they should not be mistaken for methods used in the registry record.
10. Multiplicity, Missing Data and Analysis Populations
The registry record lists 12 outcome measures, including the primary use measure and secondary outcomes concerning self-reported test results, usability, user burden, participant experience, ease, continuation, availability, and participant perspectives on implementation and changes in behavior or decision-making. It reports no analyses. No multiplicity adjustment or strategy for prioritizing among secondary outcomes is reported in the registry record.
General statistical explanation: when many outcomes or hypotheses are examined, the chance of obtaining at least one apparently unusual result by chance can increase. Prespecified outcome priorities and an appropriate multiplicity approach can help readers interpret multiple tests. Since no analyses are reported, there is no set of reported test results to assess for multiplicity, and no adjustment method should be inferred.
Handling of missing outcome data is not reported in the registry record. The record does not describe whether missing captain reports, incomplete test counts, or nonresponse to other outcomes occurred, nor how any such data would be handled. The extent of missing data and its possible influence on the results therefore cannot be assessed.
The analysis populations are not reported in the registry record. In particular, it does not specify which participants or labs would be included in an analysis, or how participants who began but did not continue using the program would be treated. The record lists enrollment of 61, but does not establish that all enrolled people contributed primary-outcome data. No interim analyses or stopping rules are reported in the registry record.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| PSOM Staff, Trainees, or Faculty Who Participate in the Point of Care Testing | 0 | 61 | 0.0% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| PSOM Staff, Trainees, or Faculty Who Participate in the Point of Care Testing | 0 of 61 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 0% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| PSOM Staff, Trainees, or Faculty Who Participate in the Point of Care Testing | 0 of 61 |
The registry record lists 61 people at risk for serious adverse events and 0 affected. It also lists 61 at risk for other adverse events and 0 affected. Deaths are recorded as 0. These are the recorded figures for the participant group described in the safety information.
These entries should be read as registry-reported counts, not as proof that no adverse events occurred in every sense. The record does not report the adverse-event definitions, collection procedures, or the completeness and timing of safety reporting. It also does not provide additional detail about how events were assessed. No serious adverse-event terms are listed.
The study description focuses on program implementation and says that test results would be self-reported. The safety figures do not measure test accuracy, program effectiveness, or the risks of testing outside the adverse-event reporting framework. With no comparative group described, these counts cannot establish whether event occurrence differed from another approach. The figures are limited to what the registry record reports.
12. What the Result Does, and Does Not, Mean
The study addresses an implementation question: how often participants used a voluntary point-of-care screening program, with use defined as the total completed tests reported over fourteen weeks. The registry record describes a program for people working in PSOM laboratories and a reporting process in which lab captains submitted lab-wide counts. It also lists enrollment of 61 and participation by 15 captains over the course of the program.
The main result needed to answer the stated primary question—the observed total of completed tests—is not reported in the registry record. No primary-outcome analysis is listed. As a result, the record does not establish the amount of program use, how precisely it was estimated, or whether use differed across labs or participants.
The endpoint also does not answer whether testing was accurate or whether the program changed clinical outcomes. The study description states that results were self-reported and would not be used to validate tests or support future FDA approval. It further says that the study would not collect samples and that no data would go into participants’ electronic medical records. These boundaries matter: reported implementation activity is not a validation study or a clinical effectiveness comparison.
The record does not describe a randomized comparison or a like-for-like control group, and the allocation method is not stated. It therefore cannot support a causal conclusion about what would have happened under an alternative program. General statistical explanation: descriptive counts can characterize recorded activity, while causal claims require a suitable comparison and assumptions that address how groups were formed. Neither the outcome total nor such a comparison is available in the registry record.
Accordingly, the record documents the program’s purpose, intended measurement, and reporting arrangement, but does not report the numerical primary result needed to quantify use. It also does not provide a basis for conclusions about accuracy, changes in behavior, or health effects.
13. Why This Trial Matters Statistically
Implementation studies ask whether a program was taken up and how it operated in its intended setting. That question is distinct from whether a test is accurate or whether a clinical intervention improves an outcome. This study’s primary measure—the total number of completed tests reported over fourteen weeks—fits the stated focus on program use.
The reporting arrangement is statistically important. Lab captains reported counts on behalf of participants, so the outcome represents lab-wide reporting rather than a stated participant-level measure. Such aggregation can be useful for monitoring activity, while limiting the detail available about individual patterns and differences between labs. The registry record does not report the distribution of counts or the completeness of reports, so those features cannot be evaluated.
The study also illustrates why an outcome definition is not the same as an interpretable result. The record states what was to be counted and who reported it, but the observed total and an analysis are not reported. Without them, readers cannot assess the amount of use or its precision. The listed enrollment does not fill that gap because it is not the primary outcome.
The distinction between implementation and validation is especially relevant because results were self-reported and were not intended to validate tests. A measure of program uptake cannot establish test performance. Likewise, without a comparison group, a descriptive count cannot show that the program caused a change in behavior or clinical outcomes. These boundaries help keep conclusions aligned with the question the study was designed to address.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The primary outcome is described, but its observed value is not reported in the registry record. This prevents assessment of program use, its variation, or its statistical precision. The record lists enrollment of 61, but does not report how many people completed tests or how the reported count was distributed among participants or labs.
Use was voluntary. The registry record does not report characteristics of participants compared with nonparticipants, so the extent to which the enrolled group reflects all eligible PSOM laboratory workers cannot be assessed. The primary outcome was reported by captains on behalf of labs. The record does not describe how those reports were checked, how complete they were, or how missing reports were handled.
No randomized comparison or like-for-like control group is described, and allocation is not stated. This limits comparative interpretation. The record also does not report a statistical analysis, an analysis population, a missing-data plan, or a multiplicity strategy. It therefore does not support conclusions about estimated differences, uncertainty, or the robustness of any findings.
The study description says that test results would be self-reported, that no samples would be collected as part of the study, and that results would not be used to validate tests. The record consequently does not provide evidence about diagnostic accuracy. It also does not report a result establishing changes in behavior, decision-making, or clinical outcomes. These are limits of the available registry information and stated study scope; they do not establish that the program lacked other effects.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: COVID-19 Screening Program — NCT05216627.
- Registry record last updated 2024-07-31; status last verified 2024-07.
- Results first posted 2024-07-31.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
The registry record describes the completed COVID-19 Screening Program, an implementation study sponsored by the University of Pennsylvania. It lists enrollment of 61 and a primary outcome measuring the total completed screening tests reported over fourteen weeks. The intended population was faculty, staff, and trainees working in person in PSOM laboratories who chose to participate in voluntary point-of-care testing.
Lab captains reported lab-wide counts on behalf of their respective labs; 15 captains participated over the course of the program. The record lists 12 outcome measures and no analyses. The observed primary outcome total is not reported in the registry record. Allocation, analysis populations, missing-data handling, and a statistical analysis plan are also not reported in the registry record.
The study description states that test results would be self-reported, would not be used to validate tests, and would not enter participants’ electronic medical records. The record’s safety entries list 0 serious adverse events, 0 other adverse events, and 0 deaths among 61 at risk.